Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine monotherapy in TRD
NCT04599855Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of esketamine in treatment-resistant depression (TRD), sponsored by Janssen Pharmaceutical. Started Nov 2020; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT04599855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04599855.